Pfizer reports positive Phase 2 infant data for next-gen pneumococcal vaccine

Pfizer (NYSE:PFE) disclosed preliminary data from its Phase 2 clinical trial evaluating PF-07872412, an investigational 25-valent pneumococcal conjugate vaccine candidate designed for pediatric use.

The findings indicate that the candidate generates robust immunogenicity and maintains a safety profile comparable to currently approved alternatives.

The data, presented at the International Society of Pneumonia and Pneumococcal Diseases meeting in Copenhagen, evaluated a four-dose regimen administered to healthy infants at two, four, six, and 12 to 15 months of age.

Results were measured against Pfizer's established Prevnar 20 vaccine.

Laboratory assessments highlighted a pronounced immune response against serotype 3, a prominent driver of residual pneumococcal disease.

One month following the third dose, geometric mean titers for serotype 3 were 8.8-fold higher in participants who received the 25-valent candidate than in those given Prevnar 20.

One month after the fourth dose, the antibody titers for the investigational candidate measured roughly 15-fold higher than the comparator group.

The next-generation candidate is designed to provide coverage for up to 90% of disease-causing pneumococcal serotypes currently tracking in children under five years old.

On the basis of these mid-stage outcomes, Pfizer confirmed plans to advance the vaccine into a Phase 3 pediatric program, targeting regulatory non-inferiority thresholds.

The safety and tolerability profile observed during the randomized trial tracked in line with existing standard-of-care pneumococcal immunizations.

Observed local reactions were limited to typical vaccination responses, such as injection site redness, swelling, and mild pain.